DEA’s New Guidance Lets Pharmacies Deliver Patient-Specific Controlled Substances to Practitioners
By Hunter DeKoninck
Published: November 6, 2026
DEA’s Diversion Control Division has issued a guidance document, Delivery of a Prescribed Controlled Substance by a DEA-Registered Pharmacy to a Practitioner for Direct Administration to the Patient under Power of Attorney (POA) (EO-DEA315), dated October 14, 2026. It answers a question that has frustrated pharmacies and clinicians for years: can a pharmacy dispense and deliver patient-specific controlled substances to a practitioner's office for administration? DEA’s answer is yes, if there is a POA in place with the patient.
Background
The Controlled Substances Act generally contemplates that a pharmacy dispenses to the ultimate user (i.e. the patient), not to the prescriber. In recent years, Congress carved out two exceptions in 21 U.S.C. § 829a(a)(2): Schedule III–V drugs injected or implanted for maintenance or detoxification treatment, and Schedule III–V drugs subject to an FDA REMS requiring monitoring after administration. DEA’s view has been that the CSA prohibits pharmacy-to-practitioner deliveries for any other types of patient-specific medication beyond these two exceptions.
DEA appreciates there are legitimate needs for certain other drugs to be delivered to practitioners for administration. Its main example is medication for intrathecal pumps used to treat intractable pain, where sterility is a concern. However, unless a practitioner uses office stock to administer medication to a patient, a practitioner can only receive patient-specific medication from a dispensing pharmacy if the patient is physically present at the office at the time of delivery. For obvious reasons, this option was never workable. So, by issuing this new guidance, DEA establishes a new process for pharmacies to be able to deliver patient-specific medication to a practitioner’s office (where the delivery is not for a MOUD or REMS drug already exempted by the CSA).
The New Process
DEA’s solution through the new guidance is POAs. In short, the patient will execute a POA naming the administering practitioner as the patient’s agent for the limited purpose of accepting delivery. The practitioner will act only as an agent and cannot do anything with the drug that the patient could not do or that the POA does not authorize. DEA sets no content requirements for the POA.
The practitioner must prescribe the medication for a named patient, not a take-home supply or office stock. The practitioner must keep the drug separate from registered stock, maintain security against theft and diversion, and administer it only to the named patient.
The pharmacy must meet all normal dispensing requirements, deliver to the address in the POA, keep records showing delivery to the practitioner by name and address, and take steps to verify that the POA exists and is valid before dispensing. DEA encourages both parties to retain the POA for at least two years after the last delivery or administration.
My Read
While this certainly is a cumbersome solution that will be difficult for the industry to operationalize, it finally gives registrants a DEA-endorsed delivery option that can be deployed without fear of being reprimanded.
In my view, as registrants roll out this process in the real world, we will end up needing more guidance from DEA. For example, this guidance tells pharmacies to verify the POA but does not say how that verification must be done. It also does not address carrier requirements, recordkeeping requirements for a practitioner’s receipt of deliveries or telehealth prescribing.
If you wish to leverage this new delivery option, consider building a clear written POA verification procedure, document deliveries and receipts, and confirm that state pharmacy law permits the arrangement before offering it.
This post is for general informational purposes and does not constitute legal advice. Consult counsel regarding your specific compliance obligations.
